ClinicalTrials.gg
RecruitingNCT06755632DEP-CBUpdated Jul 23, 2026

Screening of Patients With Hepatic Fibrosis or Cirrhosis B and C

An interventional study of TROD (rapid diagnostic orientation test) and FibroScan® in Liver Pathology, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Liver Cirrhosis by Assistance Publique - Hôpitaux de Paris — 4 open to participants now, 4 under way, none of them phase 3. Liver Cirrhosis · Assistance Publique - Hôpitaux de Paris.

Started
2025
with 1 other
No phase
5 of 16
1 open now
Registered
13th of 16
by date

Among the 16 studies in Liver Cirrhosis by Assistance Publique - Hôpitaux de Paris, this one is one of 2 that started in 2025, is one of 5 with no phase, and was the 13th registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

4 of the 16 studies in Liver Cirrhosis by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Liver Cirrhosis by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Regardless of its etiology (chronic hepatitis B or C, alcohol consumption, metabolic steatohepatitis, hemochromatosis, autoimmune liver disease), cirrhosis is a real public health issue. Cirrhosis is a chronic disease and can get complicated by liver cancer, digestive hemorrhage, or liver failure, which are responsible for morbidity and mortality.

In France, cirrhosis prevalence is estimated at 700,000 patients and induce 16,000 deaths per year (10,000 liver cancer and 6,000 liver decompensation). In Ile-de-France area, cirrhosis prevalence is estimated at 130,000 cases, a lot of them are in Seine Saint Denis department due to precariousness.

Hepatitis C virus can now be cured and hepatitis B treatment can suspend hepatitis B replication. All these treatments reduce liver complications but even after virological cure, cirrhosis requires dedicated long term management as well as alcoholic liver disease and metabolic steatohepatitis at cirrhosis stage.

Periodic screening for complications and specific measures were defined by french HAS in 2007 (medication intake, dietary management and specific vaccinations), especially the performance of a semi-annual liver ultrasound for hepatocellular carcinoma (HCC) screening.

Then, it seems essential to screen for patients with viral hepatitis and extensive fibrosis or cirrhosis in our department to achieve active and individualized management of this chronic liver disease, to reduce long term morbidity and mortality.

The main aim of the study is to evaluate the prevalence of advanced liver fibrosis and viral infections B and C in the general population of Seine Saint Denis, using a dual screening method of TROD (rapid diagnostic orientation test) and FibroScan®, combined with a care pathway

Read the detailed description

Targeted population

The targeted population will be users of one municipal health center visiting the municipal health center on a given day We will propose a screening for liver fibrosis using Fibroscan mini® and will propose rapid diagnostic orientation tests (TROD) for HCV and HBV viral infection, by a traveling physician Expérimental scheme

Proposal by the caregiver to each patient at the center :

  • Fibroscan®
  • TROD VHC / VHB IF Fibroscan ≥ 9.6 KPa or positive HCV TROD or HBsAg positive THEN Suggested appointment Avicenne hospital hepatology consultation or Jean Verdier hepatology consultation
03

Conditions studied

  • Liver Pathology

Keywords

  • Cirrhosis, Liver
  • Hepatic Cirrhosis
  • Liver Fibrosis
  • Fibrosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age≥18 years
  • Collection of signed consent
  • Patients affiliated to a Social Security System

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Subjects under AME
  • Persons under court protection
  • Guardianship or curatorship,
  • Safeguard of justice
  • Persons under psychiatric care without their consent
  • Persons admitted to a health or social institution for purposes other than research,
  • Patients of full age under legal protection (guardianship or curatorship)
  • Persons unable to express their consent.
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Patients of a municipal health center who visit the municipal health center on a given day.

    Diagnostic Test: TROD (rapid diagnostic orientation test) and FibroScan®

Interventions

  • Diagnostic testTROD (rapid diagnostic orientation test) and FibroScan®

    Fast-track appointment at the hepatology consultation at Avicenne Hospital (Bobigny) or the hepatology consultation at Jean Verdier Hospital (Bondy) for any patient : * with Fibroscan® ≥ 9.6 KPa or * positive hepatitis C serology or * HBsAg positive

06

What researchers measure

Primary outcomes

  1. Prevalence of significant hepatic fibrosis in the general population of Seine Saint Denis

    Time frame: Two year of inclusion period

Secondary outcomes

  1. Chronic hepatitis B prevalence

    Time frame: Two year of inclusion period

  2. Chronic hepatitis C prevalence

    Time frame: Two year of inclusion period

  3. Proportion of eligible patients for management of viral hepatitis B and C

    Proportion of eligible patients for management of viral hepatitis B and C

    Time frame: Two year of inclusion period

  4. Prevalence of other causes of chronic liver disease (alcohol and NASH)

    Time frame: Two year of inclusion period

  5. Proportion of patients managed in hepatology department after screening for significant fibrosis

    Time frame: Two year of inclusion period

  6. Prevalence of confirmed significant liver fibrosis in patients referred to hepatology consultation

    This criterion will be assessed based on follow-up FibroScan results, non-invasive fibrosis blood tests, and/or liver biopsy when indicated, in accordance with current hepatology guidelines.

    Time frame: Two years of inclusion period

  7. Proportion of patients with ultrasound signs of cirrhosis and hepatocellular carcinoma among patients referred to hepatology consultation (managed according to current hepatology guidelines).

    This criterion will be assessed based on abdominal ultrasound findings according to current hepatology guidelines.

    Time frame: Two years of inclusion period

07

Study locations

1 of 2 sites recruiting
  • Avicenne Hospital
    Bobigny, 93000, France
    Recruiting
  • Hepatology department -Hospital Avicenne
    Bobigny, 93100, France
    Withdrawn

    Not enrolling at this site.

08

References and documents

Publications

  • Marshall AD, Micallef M, Erratt A, Telenta J, Treloar C, Everingham H, Jones SC, Bath N, How-Chow D, Byrne J, Harvey P, Dunlop A, Jauncey M, Read P, Collie T, Dore GJ, Grebely J. Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study. Int J Drug Policy. 2015 Oct;26(10):984-91. doi: 10.1016/j.drugpo.2015.07.002. Epub 2015 Jul 16. PubMed 26256938 ↗
  • Matthews K, MacGilchrist A, Coulter-Smith M, Jones J, Cetnarskyj R. A nurse-led FibroScan(R) outreach clinic encourages socially deprived heavy drinkers to engage with liver services. J Clin Nurs. 2019 Feb;28(3-4):650-662. doi: 10.1111/jocn.14660. Epub 2018 Sep 24. PubMed 30182502 ↗
  • Chevaliez S, Pawlotsky JM. New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings. J Hepatol. 2018 Oct;69(4):916-926. doi: 10.1016/j.jhep.2018.05.017. Epub 2018 May 23. PubMed 29800630 ↗
  • Debette-Gratien M, Francois S, Chevalier C, Alain S, Carrier P, Rigaud C, Abraham B, Burgevin AL, Courat L, Debenes B, Koffi J, Caux-Nussbaum E, Zattoni-Leroy J, Feuillet-Sow G, Dumont Q, Nubukpo P, Loustaud-Ratti V. Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days. J Viral Hepat. 2023 Apr;30(4):355-361. doi: 10.1111/jvh.13798. Epub 2023 Jan 11. PubMed 36597183 ↗
  • Ganne-Carrie N, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, de Ledinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Cales P, Peron JM, Alric L, Bourliere M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grange JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Zucman D, Di Martino V, Trinchet JC, Nahon P, Roudot-Thoraval F; ANRS CO12 CirVir Study Group. Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). Hepatology. 2016 Oct;64(4):1136-47. doi: 10.1002/hep.28702. Epub 2016 Aug 4. PubMed 27348075 ↗
  • European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021 Sep;75(3):659-689. doi: 10.1016/j.jhep.2021.05.025. Epub 2021 Jun 21. PubMed 34166721 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.

Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's planned 24 months is below that.

Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2024
First posted
Jan 1, 2025
StartActual
Jun 19, 2025
Primary completionEst.
Jun 19, 2027
CompletionEst.
Jun 19, 2027
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06755632
Responsible party
Sponsor
First posted
Jan 1, 2025
Start date
Jun 19, 2025
Primary completion
Jun 19, 2027 (estimated)
Completion
Jun 19, 2027 (estimated)
Last update
Jul 23, 2026

Study contacts

Veronique GRANDO, MD-PhD
Contact
veronique.grando@aphp.fr
01 48 02 68 03 ext. +0033

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion